
EuroThrombosis & EuroVessels 2024

 ESC Working Group on Thrombosis together with the ESC Working Group on Aorta and Peripheral Vascular Diseases



Preliminary Programme





Preliminary Scientific Programme

Thursday, October 10th, 2024

14:00-15:30 Parallel hands-on tutorials (15 participants each)

- WG Thrombosis: How to start a career as a cardiovascular basic scientist Lina Badimon, Barcelona, SP
- WG APVD: From heart to toes: echo, MRT and duplexsonographic imaging Christine Espinola-Klein, Mainz, DE; José Rodríguez Palomares, Barcelona, SP
- WG Thrombosis: intravascular imaging and plaque vulnerability Simone Biscaglia, Ferrara, IT
- WG APVD: Cardiovascular genetics for non-genetic cardiovascular specialists Julie de Backer, Gent, BE; Roland van Kimmenade, Nijmegen, NL

15:30-16:00 Opening lecture

Presenter: Andrea Rubboli, Ravenna, IT

Individualization of antiplatelet therapy in the first year after ACS: state of the art

Marco Valgimigli, Lugano, CH

16:00-17:15 Session 1. Anticoagulation therapy in special clinical contexts

Chair: Dan Atar, Oslo, NO; José Luis Ferreiro, Barcelona, SP

- Audience survey Pre
- Severe infections Bruna Gigante, Stockholm, SE
- Obesity Bianca Rocca, Rome, IT
- · Cardiogenic shock Christophe Vandenbriele, Leuven, BE
- Audience survey Post
- Interactive discussion (chairs + speakers + audience)

16:00-17:15 Session 1A. Podium discussion on news and gaps in peripheral arterial disease and

aortic diseases - hot topic

Podium: Gisela Teixidó, SP; Eugenio Estabile, IT; Marianne Brodmann, AT; Julie De Backer, BE

17:15-17:45 Coffee break and exhibition

17:45-18:15 Doppler lecture

Vascular medicine in 2024 - the role of air pollution

Jill Belch, Dundee, UK

18:15-19:15 Satellite Symposium - TBC

Friday October 11th, 2024

08:00-09:15 Session 2: Factor XI inhibition in cardiovascular diseases: where are we?

Chair: Christine Espinola-Klein, Mainz, DE; Gregory Lip, Liverpool, UK

- Audience survey Pre
- Myocardial infarction Gianluca Campo, Ferrara, IT
- Atrial fibrillation Dan Atar, Oslo, NO
- Venous thromboembolism Marianne Brodmann, Graz, AT
- · Audience survey Post
- Interactive discussion (chairs + speakers + audience)

08:00-09:15 Session 2A. The future in genetic vascular diseases

Chairs: Julie De Backer, Gent, BE; Gemma Vilahur, Barcelona, SP

- Future Research models in Marfan syndrome: ups and downs Patrick Sips, Gent, BE
- Imaging in genetic vascular diseases José Rodríguez Palomares, Barcelona, SP
- Cardiovascular burden in genetic vascular diseases Guillaume Jondeau, FR
- Combining machine learning and genes in aortic disease: the unmissing link Andrea Guala, Barcelona, SP
- Wrap up by chairs

09:15-10:30 Session 3. Mechanical treatment and prevention of thrombosis: an update

Chair: Stavros Konstantinides, Mainz, DE; Jurrien Ten Berg, Nieuwegein, NL

- Audience survey Pre
- · Thrombectomy in acute pulmonary embolism Piotr Pruszczyk, Warsaw, PL
- Cerebral protection during cardiac interventions Tobias Geisler, Tubingen, DE
- Acute or chronic when to intervene in deep vein thrombosis Oliver Schlager, Vienna, AT
- Audience survey Post
- Interactive discussion (chairs + speakers + audience)

09:15-10:30 Session 3A. New goals in the management of peripheral arterial disease

Chair: Marco De Carlo, Pisa, IT; Alessandra Bura-Riviere, Toulouse, FR

- How to manage hypertension in vascular diseases Victor Aboyans, Limoges, FR
- How to treat diabetes in vascular diseases Christine Espinola-Klein, Mainz, DE
- Nutrition and dietary pattern in vascular patients Christian Heiss, Redhill, UK
- · Management of PAD in women does it differ? Alessandra Bura, Riviere, Toulouse,
- Wrap up by chairs

10:30-11:00 Coffee break and exhibition

11:00-11:45 Session 4 (Case-based). Innovations in parenteral antiplatelet therapy for STEMI patients

Chair: Joao Morais, Leiria, PT; Diana A Gorog, London, UK

- Clinical case presentation (Acute stent thrombosis) William AE Parker. Sheffield, UK
- Pharmacology of selatogrel and zalunfiban José Luis Ferreiro, Barcelona, SP
- Selatogrel or zalunfiban would have changed the clinical outcome:
- · Yes Jurrien Ten Berg, Nieuwegein, NL
- No Eliano P. Navarese, Sassari, IT
- Interactive discussion (chairs + speakers + audience)







11:00-11:45 Session 4A. Debated in Aortic diseases

Chair: José Rodríguez Palomares, Barcelona, SP; Guillaume Jondeau, FR

- New biomarkers in risk stratification: from indexation to biomechanics -Gisela Teixidó, Barcelona, SP
- Aortic surgery in women: should we use the same thresholds? Matthias Thielmann, DE
- New endovascular devices: can we shift the indications of open surgery? Mauro Gargiulo, Bologna, IT
- · Wrap up by the chairs

11:45-12:45 Case-based session (Organized by WG on Thrombosis Young Researchers Group)

Chair: Dario Bongiovanni, Munich, DE; William AE Parker, Sheffield, UK; Christine Espinola-Klein, Mainz, DE

13:00-14:00 Sponsored lunch symposium - TBD

14:30-15:00 Lecture

Presenter: Diana A Gorog, London, UK

Certainties and remanining uncertainties in the prevention of stroke after the 2024 guidelines on atrial fibrillation - *Gregory Lip, Liverpool, UK*

15:00-16:15 Session 6. Advances in the pathogenesis of thrombosis

Chair: Lina Badimon, Barcelona, SP; Roland van Kimmenade, Nijmegen, NL

- Clot structure, function and endogenous fibrinolysis Nicola Mutch, Aberdeen, UK
- Circulating miRNAs: their potential as therapeutic targets to prevent thrombosis -Gemma Vilahur, Barcelona, SP
- The role of inflammation in aortic disease Patrick Sips, Gent, BE
- Thromboinflammation: novel molecular insights in platelet-leukocite interactions Heleen Van Beusekom, Rotterdam, NL
- Interactive discussion (chairs + speakers + audience)

15:00-16:15 Session 6A. Lipid management in cardiovascular diseases

Chair: Christian Heiss, Redhill, UK; Oliver Schlager, Vienna, AT

- Peripheral arterial disease which drug for which patient Tristan Mirault, Paris, FR
- Intravascular imaging in coronary artery disease Gianluca Campo, Ferrara, IT
- Role of lipid management in aortic diseases Marco De Carlo, Pisa, IT
- Venous thromboembolism is lipid lowering an issue? Stavros Konstantinides, Mainz, DE
- Wrap up by chairs

16:15-16:45 Coffee break and exhibition

16:45-17:15 Steen Husted lecture

Presenter: Joao Morais, Leiria, PT

From willow bark to the present day: the long journey of aspirin and its clinical applications

- Carlo Patrono, Rome, IT

17:15-18:15 Satellite Symposium

18:30 - 19:30 Parallel WG General Assemblies



Saturday October 12th, 2024

08:00-09:15 Session 7. Inflammation, atherosclerosis and thrombosis

Chair Bruna Gigante, Stockholm, SE; Eliano Navarese, Sassari, IT

- Targeting inflammation to reduce the atherothrombotic risk Robert F. Storey, Sheffield, UK
- PCKS9 inhibitors, bempedoic acid and inclisiran: no excuses anymore to not reach
 LDL- cholesterol targets Felice Gragnano, Naples, IT
- Lp(a) and triglycerides: additional therapeutic targets beyond LDL-cholesterol -Claudio Borghi, Bologna, IT
- Cardiovascular risk stratification and indications for GLP-1 receptor agonists and SGLT2 inhibitors in patients with diabetes - Christina Christersson, Uppsala, SE
- Interactive discussion (chairs + speakers + audience)

08:00-09:15 Session 7A. Exercise training in cardiovascular diseases

Chair: Alessandra Bura-Riviere, Toulouse, FR; Mauro Gargiulo, Bologna, IT

- Exercise, inflammation and the coagulation system Jörn Fredrik Dopheide, CH
- Exercise or revascularization in PAD choose or combine? Marianne Brodmann, Graz, AT
- Exercise in aortic disease dos and don'ts Roland van Kimmenade, Nijmegen, NL
- Patient education and home-based training in cardiovascular diseases Lucia Mazzolai, Lausanne, CH
- · Wrap up by chairs

09:15-10:30 Moderated posters (Organized by WG on Thrombosis Young Researchers Group)

Chair: Dario Bongiovanni, Munich, DE; Christophe Vandenbriele, Leuven, BE; Lina Badimon, Barcelona, SP

09:15-10:30 Moderated posters (WGAPVD)

Chair: Tristan Mirault, Paris, FR; José Rodríguez Palomares, Barcelona, SP

10:30-11:00 Coffee break and exhibition

11:00-12:00 Session 8. Long-term SAPTS after ACS should include P2Y12 inhibitor instead of aspirin

Chair: Robert F. Storey, Sheffield, UK; Tobias Geisler, Tubingen, DE

- Audience survey Pre
- Yes Felice Gragnano, Naples, IT
- No Bianca Rocca, Rome, IT
- Audience survey Post
- Interactive discussion (chairs + speakers + audience)





11:00-12:00: Session 8A. Dual pathway inhibition for all patients with peripheral arterial disease

Chair: Lucia Mazzolai, CH; Marco de Carlo, Pisa, IT

- Audience survey Pre
- Yes Marco De Carlo, Pisa, IT
- No Maarit Venermo, Helsinki, Fl
- Audience survey Post
- On-stage discussion

12.00-12:30 Closing lecture

"The role of Genotypic and Phenotypic features in predicting the risk in Thoracic Aortic disease" - Guillaume Jondeau, FR

12:30-13:00 Poster awards and closing of congress

Andrea Rubboli, Ravenna, IT; Diana A Gorog, London, UK; Oliver Schlager, Vienna, AT; José Rodríguez Palomares, Barcelona, SP



Bco Congresos ESC Working Group on Thrombosis together with the ESC Working Group on Aorta and Peripheral Vascular Diseases Technical Secretariat Plaza de Europa, 17-19 08908 L'Hospitalet de Llobregat Barcelona (Spain) etev2024@bcocongresos.com